Related references
Note: Only part of the references are listed.Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach COMMENT
Daniel A. Arber et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
John Mascarenhas et al.
BLOOD (2022)
How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond
Donal P. McLornan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
Ayalew Tefferi et al.
CANCER RESEARCH (2022)
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
Paola Guglielmelli et al.
BLOOD ADVANCES (2022)
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond
Chandan Saha et al.
BLOOD REVIEWS (2022)
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
Jean-Jacques Kiladjian et al.
LEUKEMIA (2022)
Recent advances in the treatment of polycythemia vera
Adrian Duek et al.
LEUKEMIA & LYMPHOMA (2022)
Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases
Naseema Gangat et al.
BLOOD CANCER JOURNAL (2022)
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
Monia Marchetti et al.
Lancet Haematology (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis
Jan Philipp Bewersdorf et al.
LEUKEMIA (2021)
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations
Naseemap Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
A Globally Applicable Triple AAA Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count
Ayalew Tefferi et al.
BLOOD (2021)
Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre
Paul Deschamps et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
Paola Guglielmelli et al.
BLOOD CANCER JOURNAL (2021)
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients
Giuseppe G. Loscocco et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
Paola Guglielmelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Ayalew Tefferi et al.
LEUKEMIA (2021)
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
Emanuela Sant'Antonio et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
Lukas Ronner et al.
BLOOD (2020)
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
Paola Guglielmelli et al.
BLOOD CANCER JOURNAL (2020)
The new WHO classification for essential thrombocythemia calls for revision of available evidences
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2020)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
Alessandra Carobbio et al.
BLOOD CANCER JOURNAL (2020)
Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls
Nabih Maslah et al.
ANNALS OF HEMATOLOGY (2019)
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
Tarinee Rungjirajittranon et al.
BMC CANCER (2019)
3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
Natasha Szuber et al.
MAYO CLINIC PROCEEDINGS (2019)
Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
Rangit R. Vallapureddy et al.
BLOOD CANCER JOURNAL (2019)
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2019)
Essential Thrombocythemia
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology
Ljubomir Jakovic et al.
ANNALS OF HEMATOLOGY (2018)
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms A Population-Based Cohort Study
Malin Hultcrantz et al.
ANNALS OF INTERNAL MEDICINE (2018)
Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia
Ayako Kamiunten et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
MIPSS70+Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
Ayalew Tefferi et al.
LEUKEMIA (2018)
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Ayalew Tefferi et al.
LEUKEMIA (2018)
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2018)
Polycythemia vera treatment algorithm 2018
Ayalew Tefferi et al.
BLOOD CANCER JOURNAL (2018)
Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger
Natasha Szuber et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
What is pre-fibrotic myelofibrosis and how should it be managed in 2018?
Natalia Curto-Garcia et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
MPL-mutated essential thrombocythemia: a morphologic reappraisal
Natasha Szuber et al.
BLOOD CANCER JOURNAL (2018)
Prefibrotic myelofibrosis: treatment algorithm 2018
Guido Finazzi et al.
BLOOD CANCER JOURNAL (2018)
Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons
Mythri Mudireddy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance
Daniela Barraco et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations
Umberto Gianelli et al.
MODERN PATHOLOGY (2017)
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Guilin Tang et al.
HAEMATOLOGICA (2017)
Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome
Meera Yogarajah et al.
MAYO CLINIC PROCEEDINGS (2017)
Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations
D. Barraco et al.
BLOOD CANCER JOURNAL (2017)
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria
Elisa Rumi et al.
ONCOTARGET (2017)
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Guilin Tang et al.
HAEMATOLOGICA (2017)
Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia
Hans Michael Kvasnicka et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease
Georg Jeryczynski et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria
Kyohei Misawa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
Paola Guglielmelli et al.
BLOOD (2017)
Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version
Alessandra Iurlo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes
Alberto Alvarez-Larran et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study
Hans Michael Kvasnicka et al.
HISTOPATHOLOGY (2016)
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
H. Gisslinger et al.
LEUKEMIA (2016)
The prognostic impact of bone marrow fibrosis in primary myelofibrosis
Paola Guglielmelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Refining prognostication of thrombosis in ET
Tiziano Barbui
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients
Mahnur Haider et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances
T. Barbui et al.
BLOOD REVIEWS (2016)
MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia
M. Haider et al.
BLOOD CANCER JOURNAL (2016)
Targeted deep sequencing in primary myelofibrosis
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2015)
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
T. Barbui et al.
BLOOD CANCER JOURNAL (2015)
The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading
O. Pozdnyakova et al.
LEUKEMIA (2015)
The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis
T. Barbui et al.
LEUKEMIA (2015)
Masked polycythemia Vera (mPV): Results of an international study
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
Ayalew Tefferi et al.
BLOOD (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes
Alberto Alvarez-Larran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera
Federico Lussana et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Rethinking the diagnostic criteria of polycythemia vera
T. Barbui et al.
LEUKEMIA (2014)
Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis
Richard T. Silver et al.
BLOOD (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
J. V. Jovanovic et al.
LEUKEMIA (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update
Hans Michael Kvasnicka
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia
Alessandra Carobbio et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Brief report Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
Tiziano Barbui et al.
BLOOD (2012)
Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
Malin Hultcrantz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis
Umberto Gianelli et al.
MODERN PATHOLOGY (2012)
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
G. Finazzi et al.
LEUKEMIA (2012)
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification
Juergen Thiele et al.
BLOOD (2011)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
Alessandra Carobbio et al.
BLOOD (2011)
The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera
Khadija Abdulkarim et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance
Naseema Gangat et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis
Juergen Thiele et al.
Current Hematologic Malignancy Reports (2008)
Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis
Claudia Vener et al.
BLOOD (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera
Hans Michael Kvasnicka et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Grade of bone marrow fibrosis is associated with relevant hematological findings - a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis
J Thiele et al.
ANNALS OF HEMATOLOGY (2006)
Share Paper
